3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Warts
1
Neutropenia
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Leukopenia
1
Leukemia, Plasma Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Infections
1
Immunologic Deficiency Syndromes
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Agammaglobulinemia
1
Acquired Immunodeficiency Syndrome
1
Interventions
Cyclophosphamide
34
Doxorubicin
24
fludarabine phosphate
20
Vinblastine
20
Nivolumab
20
Dacarbazine
20
Brentuximab Vedotin
20
pembrolizumab
19
fludarabine
18
Mycophenolic Acid
17
Whole-Body Irradiation
15
Etoposide
14
Filgrastim
13
Melphalan
12
Granulocyte Colony-Stimulating Factor
10
Gemcitabine
10
Bleomycin
10
Tacrolimus
9
Radiotherapy
9
Prednisone
9
Peripheral Blood Stem Cell Transplantation
9
Busulfan
9
Specimen Handling
8
Vincristine
7
Sirolimus
7
Magnetic Resonance Spectroscopy
7
Cyclosporine
7
pegfilgrastim
6
Stem Cell Transplantation
6
Bendamustine Hydrochloride
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hodgkin Disease
×
plerixafor
×
1 year
×
Clear all
NCT07188090
2025-11-28
HSCT
Thomas Jefferson University
Phase 2
Recruiting
100 enrolled